Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.

NCT06356922 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Acute Leukemia

Interventions

DRUG: Experimental drug [177Lu]Lu-PentixaTher

Sponsor

Nantes University Hospital